Bronchiolitis Obliterans Syndrome Pipeline Analysis Report 2025

Bronchiolitis obliterans syndrome (BOS) is a severe, progressive lung disorder characterized by inflammation and fibrosis of the small airways, leading to irreversible airflow obstruction. According to Guang-Shing Cheng et al., 2025, BOS and other late-onset noninfectious pulmonary complications (LONIPCs) affect as many as 20% of allogeneic hematopoietic cell transplant (HCT) recipients, contributing to significant morbidity and mortality for individuals who have been cured of hematologic disease. According to the bronchiolitis obliterans syndrome pipeline analysis by Expert Market Research, increasing prevalence and the urgent need for effective therapies are expected to drive significant growth in the coming years.

Report Coverage

The Bronchiolitis Obliterans Syndrome Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bronchiolitis obliterans syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bronchiolitis obliterans syndrome. The bronchiolitis obliterans syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The bronchiolitis obliterans syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with bronchiolitis obliterans syndrome guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bronchiolitis obliterans syndrome.

Bronchiolitis Obliterans Syndrome Pipeline Outlook

Bronchiolitis obliterans syndrome (BOS) is a progressive, non-reversible lung disease characterized by inflammation and fibrosis of the small airways, often occurring after allogeneic hematopoietic cell transplantation or lung transplantation. It develops due to immune-mediated injury, chronic graft-versus-host disease, infections, or toxic insults, leading to airflow obstruction, reduced lung function, and respiratory decline.

Bronchiolitis obliterans syndrome treatments include immunosuppressive therapy, corticosteroids, anti-fibrotic agents, and targeted biologics to manage inflammation, slow fibrosis, and improve lung function in affected patients. An example from the Bronchiolitis Obliterans Syndrome market drug pipeline is ruxolitinib. In February 2025, a study demonstrated significant improvement in lung function, particularly in patients diagnosed within six months. The drug achieved a median National Institutes of Health response time of 7.7 months and represents a promising approach for managing fibrosis and inflammation in BOS patients.

Bronchiolitis Obliterans Syndrome Epidemiology

The bronchiolitis obliterans syndrome (BOS) drug pipeline is rapidly evolving to tackle the growing clinical challenges and unmet patient needs. Guang-Shing Cheng et al., 2025, report that BOS and other late-onset noninfectious pulmonary complications affect up to 20% of allogeneic hematopoietic cell transplant recipients. Jacqueline S. Dickey et al., 2024, note that chronic graft-versus-host disease impacts 50% of these patients, with lung involvement manifesting as BOS in 5-14% of cases. Pipeline advancements aim to address these unmet medical needs.

Bronchiolitis Obliterans Syndrome - Pipeline Therapeutic Assessment

This section of the report covers the analysis of bronchiolitis obliterans syndrome drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The bronchiolitis obliterans syndrome pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Polymers

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Bronchiolitis Obliterans Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 52%, holds the largest share of the total bronchiolitis obliterans syndrome clinical trials. It is followed by phase I at 25%, reflecting strong mid-stage development. Phase III, at 11.76%, indicates ongoing late-stage progress. This distribution underscores a robust and advancing pipeline, with the progression of these therapies through clinical phases expected to expand treatment options, improve patient outcomes, and drive market growth.

Bronchiolitis Obliterans Syndrome Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the bronchiolitis obliterans syndrome pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides and polymers. The bronchiolitis obliterans syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for bronchiolitis obliterans syndrome. In the bronchiolitis obliterans syndrome drug pipeline, immunosuppressive therapies are advancing as potential treatments. For example, Liposomal Cyclosporine A for Inhalation (L-CsA-i) is under Phase III evaluation in the BOSTON-3 extension trial. Administered via the eFlow® Technology nebulizer, it targets T-cell-mediated airway inflammation post single or double lung transplant, aiming to improve long-term outcomes and reduce disease progression.

Bronchiolitis Obliterans Syndrome Clinical Trials - Key Players

The report for the bronchiolitis obliterans syndrome pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bronchiolitis obliterans syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in bronchiolitis obliterans syndrome clinical trials:

• Renovion, Inc.
• OrphAI Therapeutics
• Incyte Corporation
• Qurient Co., Ltd.
• Sanofi
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Nevro Corp
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Rigel Pharmaceuticals
• Beijing Tide Pharmaceutical Co., Ltd.

Bronchiolitis Obliterans Syndrome - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bronchiolitis obliterans syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bronchiolitis obliterans syndrome drug candidates.

Drug: ARINA-1

ARINA-1 is a novel nebulized immunomodulatory agent sponsored by Renovion, Inc. This Phase 3 study is evaluating ARINA-1 in preventing the progression of bronchiolitis obliterans syndrome (BOS) in participants with bilateral lung transplants. The study is examining ARINA-1’s ability to improve quality of life, reduce airway inflammation, and delay the need for augmented immunosuppression compared to Standard of Care. ARINA-1 is actively restoring lung function by clearing mucus and modulating immune responses.

Drug: LAM-001

LAM-001 is a proprietary dry powder inhaled formulation of sirolimus. It is under evaluation in lung transplant recipients with bronchiolitis obliterans syndrome (BOS) under the INSPO-BOS study. Sponsored by Steven Hays, MD, at the University of California, San Francisco, this Phase 2 trial is examining the safety, tolerability, and efficacy of LAM-001 in slowing BOS progression. Participants are inhaling LAM-001 or placebo daily for 48 weeks, while undergoing pulmonary testing, bronchoscopy, lab evaluations, and home spirometry monitoring. The study is also assessing mTOR pathway inhibition and sirolimus lung deposition, aiming to reduce systemic toxicity compared to oral therapy.

Key Questions Answered in the Bronchiolitis Obliterans Syndrome Pipeline Insight Report

• Which companies/institutions are leading the bronchiolitis obliterans syndrome drug development?
• Which company is leading the bronchiolitis obliterans syndrome pipeline development activities?
• What is the current bronchiolitis obliterans syndrome commercial assessment?
• What are the opportunities and challenges present in the bronchiolitis obliterans syndrome pipeline landscape?
• What is the efficacy and safety profile of bronchiolitis obliterans syndrome pipeline drugs?
• Which company is conducting major trials for bronchiolitis obliterans syndrome drugs?
• Which companies/institutions are involved in bronchiolitis obliterans syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in bronchiolitis obliterans syndrome?

Reasons To Buy This Report

The Bronchiolitis Obliterans Syndrome Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bronchiolitis obliterans syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bronchiolitis obliterans syndrome collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.